- BrePco Biopharma and Aspire Pharma announce UK license and CMC development agreement for Neoatricon
- BrePco Biopharma announce the presentation of selected results of late-stage clinical trial in extremely premature neonates
- Announcing Commencement of Dosing in Hypotension in Premature Neonates (“HiP”) Phase III Clinical Trial
- IRISH COMPANY BREPCO BIOPHARMA ANNOUNCES €5.66 MILLION IN FUNDING FOR RESEARCH INTO THE TREATMENT OF ILL PREMATURE BABIES
- 2011 Bio International Convention
- Website Launched!
